Ocumetics Technology Corp (OTC) Stock Price & Analysis

26 Followers

OTC Stock Chart & Stats

CA$0.40-CA$0.01(-1.25%)

At close: Nov 10 4:00 PM EST

Day’s Range: CAD 0.40 - CAD 0.40
52-Week Range: CAD 0.35 - CAD 1.06
Previous Close: CAD 0.40
Volume: N/A
Average Volume (3M): 20.54K
Market Cap: CAD 56.87M
Enterprise Value: CAD 63.76M
Total Cash (Recent Filing): CAD 88.74K
Total Debt (Recent Filing): CAD 4.31M
Price to Earnings (P/E): ―
Beta: 0.90
Next Earnings: Dec 01, 2026 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Focused Ophthalmology Specialization

A concentrated focus on ophthalmology gives the company a clearly defined market and development objective. Specialization in vision-correction technology can support focused research, regulatory preparation, and commercialization planning if the company advances its lead implant toward broader clinical adoption.

Differentiated Lead Product Opportunity

The lead product targets a substantial vision-correction need while aiming to offer an alternative to existing eyewear and cataract-lens approaches. If development and regulatory preparation progress, this product positioning could create a distinct commercial opportunity within ophthalmic implants.

Lower Debt Versus Prior Period

The reduction in total debt from 2025 to the trailing twelve-month period is a modest improvement in the capital structure. It may lessen near-term debt burden relative to the prior period, although the benefit is limited because the company still has negative equity and substantial leverage.

Bears Say

No Meaningful Commercialization Yet

Persistent zero revenue indicates that the company has not yet converted its technology development efforts into commercial sales. This leaves future funding dependent on continued external support and makes the business highly sensitive to delays in development, regulatory progress, or market launch.

Widening Operating Losses

The progression toward larger net losses shows that expenses are rising faster than any offsetting revenue, moving profitability further away. Continued losses can consume capital needed for research and commercialization, while increasing the amount of funding required before the product generates operating income.

Negative Equity And Ongoing Cash Burn

Negative shareholders’ equity signals a weak capitalization base, while recurring operating and free-cash-flow deficits show that the company is not self-funding its activities. Together, these conditions increase reliance on external financing and create sustained dilution and financial-flexibility risk.

Ocumetics Technology Corp News

Ocumetics Strengthens Board Leadership Amid Push to Fund Vision-Tech Trials

Ocumetics Technology Corp ( ($TSE:OTC) ) has provided an announcement. Ocumetics Technology Corp. has reshaped its board leadership, appointing venture capitalist and fintech entrepreneur Sandi Gilbert as a director and

1w ago2QB0 OTC

Ocumetics Marks Key 12-Month Milestone in First-in-Human Lens Trial

An update from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp. reported that Group One patients in its first-in-human clinical trial of the Ocumetics accommodating intraocular

1M ago2QB0 OTC

Ocumetics Advances Next-Gen Intraocular Lens Trials With Group Two Recruitment

An announcement from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp. has begun recruiting patients in Mexico City for Group Two of its human clinical study

2M ago2QB0 OTC

Ocumetics Readies Next-Gen Intraocular Lens for Second Human Trials

Ocumetics Technology Corp ( ($TSE:OTC) ) just unveiled an announcement. Ocumetics Technology Corp. has completed manufacturing of its next-generation solid state accommodating intraocular lenses, clearing the way for Group Two

2M ago2QB0 OTC

Ocumetics Completes Final Tranche of $3.1 Million Private Placement to Advance Lens Trials

Ocumetics Technology Corp ( ($TSE:OTC) ) just unveiled an update. Ocumetics Technology Corp. has completed the third and final tranche of its previously announced unit private placement. In this last

2M ago2QB0 OTC

Ocumetics Advances First-in-Human Lens Trials After Productive ASCRS Meetings

An announcement from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp., a Canadian developer of next-generation intraocular lenses and other vision correction technologies, is conducting first-in-human

7M ago2QB0 OTC

Ocumetics to Court Strategic Partners as First-In-Human Lens Data Debuts at ASCRS

Ocumetics Technology Corp ( ($TSE:OTC) ) just unveiled an announcement. Ocumetics Technology Corp., a Canadian ophthalmic technology developer, is advancing a first-in-human feasibility study for its accommodating intraocular lens, which

7M ago2QB0 OTC

Ocumetics Unveils Streamlined Breakthrough Design for Next-Generation Intraocular Lens

Ocumetics Technology Corp ( ($TSE:OTC) ) has shared an update. Ocumetics Technology Corp. announced major design breakthroughs in its accommodating intraocular lens platform, the Ocumetics Lens, achieved through collaboration with

7M ago2QB0 OTC

Ocumetics Grants Stock Options to IR Advisor as It Advances Novel Intraocular Lens

An update from Ocumetics Technology Corp ( ($TSE:OTC) ) is now available. Ocumetics Technology Corp., a Canadian ophthalmic R&D company developing advanced intraocular lenses and other vision-enhancing technologies, is currently

8M ago2QB0 OTC

Ocumetics forms scientific advisory committee to steer late-stage development of accommodating intraocular lens

Ocumetics Technology Corp ( ($TSE:OTC) ) just unveiled an announcement. Ocumetics Technology Corp., a developer of next-generation ophthalmic devices, is advancing a novel intraocular lens designed to sit in the

8M ago2QB0 OTC

OTC FAQ

What was Ocumetics Technology Corp’s price range in the past 12 months?

Ocumetics Technology Corp lowest stock price was C$0.35 and its highest was C$1.06 in the past 12 months.

What is Ocumetics Technology Corp’s market cap?

Ocumetics Technology Corp’s market cap is C$56.87M.

When is Ocumetics Technology Corp’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Ocumetics Technology Corp’s earnings last quarter?

Ocumetics Technology Corp released its earnings results on Aug 28, 2026. The company reported -C$0.004 earnings per share for the quarter.

Is Ocumetics Technology Corp overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Ocumetics Technology Corp pay dividends?

Ocumetics Technology Corp does not currently pay dividends.

What is Ocumetics Technology Corp’s EPS estimate?

Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Ocumetics Technology Corp have?

Ocumetics Technology Corp has 143,983,700 shares outstanding.

What happened to Ocumetics Technology Corp’s price movement after its last earnings report?

Ocumetics Technology Corp reported an EPS of -C$0.004 in its last earnings report. Following the earnings report the stock price went up 1.149%.

Which hedge fund is a major shareholder of Ocumetics Technology Corp?

Currently, no hedge funds are holding shares in TSE:OTC

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description